RepliCel Life Sciences, a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to provide an update on the licensing and co-development of its RCH-01 product with Shiseido Company.
Sarepta Therapeutics, a developer of innovative RNA-targeted therapeutics, today announced that it has priced an underwritten public offering of an aggregate of 5.02 million shares of its common stock.
From diagnostics to drug development, the genetics industry provides information biotech, pharma and medical device companies need to continue making innovative products. That’s why we’re counting down some significant players in genetics and genomics—those companies that splice and edit their days away, developing technologies and tests that are so key
BioNTech AG announced today that it will collaborate with the Roche Group’s Genentech on new messenger RNA-based vaccines that will prevent or treat various types of cancer.
Veracyte, a company providing genomic solutions in molecular cytology, has announced that Palmetto GBA posted a draft local coverage determination (LCD) for their Percepta Bronchial Genomic Classifier. The move follows the posting by Noridian Health on September 8, 2016.
CRISPR-Cas9 is revolutionizing gene engineering. And for those keen on the sector, there is ample opportunity to break into this market, thanks to the rise of CRISPR-based biotechs like Editas Medicine or Intellia Therapeutics. But before you buy in, read on. This emerging technology has plenty of potential—but also a
Biogen today announced it will report third quarter 2016 financial results on Wednesday, October 26, 2016, before the financial markets open. Following the release of the financials, the Company will host a live webcast where Biogen management will discuss the financial results, at 8:30 am ET.
Interpace Diagnostics Group (NASDAQ: IDXG) announced that it will have two poster presentations at the 86th Annual Meeting of the American Thyroid Association, which takes place on September 15, 2016. These studies will focus on product candidates ThyGenX and ThyraMir.
Abeona Therapeutics, a clinical-stage biopharmaceutical company focused on delivering gene therapy for life-threatening rare diseases, announced that the fifth patient was enrolled in the Phase 1/2 clinical trial for EB-101 (gene-corrected skin grafts).
Cellectis S.A., a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced its results for the three-month period ended June 30, 2016 and for the six-month period ended June 30, 2016.
J. Craig Venter’s company is working to create a private database of genetic information through a partnership with insurance company Discovery Health.